(Q39447961)

12 September 2017

title

Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma (English)

1 reference

12 September 2017

1 reference

1 reference

1 reference

G W Middleton

1

1 reference

12 September 2017

I E Smith

2

1 reference

12 September 2017

M E O'Brien

3

1 reference

12 September 2017

A Norton

4

1 reference

12 September 2017

T Hickish

5

1 reference

12 September 2017

K Priest

6

1 reference

12 September 2017

L Spencer

7

1 reference

12 September 2017

S Ashley

8

1 reference

12 September 2017

publication date

1 March 1998

1 reference

12 September 2017

1 reference

12 September 2017

volume

9

1 reference

12 September 2017

issue

3

1 reference

12 September 2017

page(s)

269-273

1 reference

Chemotherapy in malignant mesothelioma: a review

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Chemotherapy in malignant pleural mesothelioma. A review.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Cisplatin and cytarabine administered intrapleurally as treatment of malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236010868

7 January 2021

Identifiers

DOI

10.1023/A:1008236010868

1 reference

12 September 2017

1 reference